Bionano Genomics Inc. (BNGO)
BNGO trades on Nasdaq in Industrials, Biotechnology: Laboratory Analytical Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1411690/000141169026000007/0001411690-26-000007-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | BNGO on Nasdaq |
| Sector | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001411690 |
| SEC industry code | Laboratory Analytical Instruments |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $28.5M |
| Net income | -$26.4M |
| Operating income | -$33.3M |
| Net margin | -92.6% |
| Operating margin | -116.9% |
| Revenue growth | -7.4% |
| Cash | $3.0M |
| Total assets | $73.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Management has prepared cash flows forecasts which indicate that based on the Company's expected operating losses and negative cash flows, there is substantial doubt about the Company's ability to continue as a going concern within twelve months after the date that the unaudited condensed consolidated financial statements for the nine months ended September 30, 2026, are issued." | 10-Q 2026-11-10 |
| Cash and burn | $4.4M cash; operating cash flow -$4.8M a quarter. | Report 2026-09-30 |
| Shares outstanding | 13,989,000 (2026-11-04); 10,176,000 a year earlier; 38,840,337 three years earlier. 3y figure adjusted for splits (1-for-60 overall). | Cover page 2026-11-04 |
| Reverse splits, 3 years | 1; latest 1-for-60 on 2025-01-27 | Source 2025-01-27 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-05-08 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | BDO USA, P.C., San Diego, California, United States | PCAOB Form AP 2026-03-25 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $10K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $8.3M | -$6.5M | -$4.5M | $4.4M | No debt tags | $31.1M | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | $8.2M | -$7.4M | -$4.7M | $3.7M | No debt tags | $30.2M | 10-Q 2026-08-10 |
| Q1 2026 2026-03-31 | $6.7M | -$8.3M | -$5.7M | $3.4M | No debt tags | $28.7M | 10-Q 2026-05-13 |
| Q4 2025 2025-12-31 | $8.0M | -$7.9M | -$4.2M | $3.0M | No debt tags | $28.5M | 10-K 2026-03-23 |
| Q3 2025 2025-09-30 | $7.4M | -$8.5M | -$5.9M | $3.1M | No debt tags | $28.7M | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | $6.7M | -$6.9M | -$3.5M | $3.6M | No debt tags | $27.4M | 10-Q 2026-08-10 |
| Q1 2025 2025-03-31 | $6.5M | -$3.1M | -$2.8M | $3.6M | No debt tags | $28.5M | 10-Q 2026-05-13 |
| Q4 2024 2024-12-31 | $8.2M | -$20.1M | -$6.5M | $9.2M | No debt tags | $30.8M | 10-K 2026-03-23 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-11-05 |
| Latest annual report | 10-K | 2026-03-23 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report | 8-K | 2026-11-10 |
| Latest proxy | DEFA14A | 2026-04-02 |
Source: SEC EDGAR submissions feed, 634 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -13.0% |
| 1 month | -26.5% |
| 3 months | -15.3% |
| Year to date | -34.6% |
| 1 year | -32.0% |
| From 52-week high | -45.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Laboratory Analytical Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CIRC | Circle8 Group Inc. | $0.1702 | -7.30% | $20.0M |
| ASTC | Astrotech Corporation (DE) | $3.76 | -10.48% | $8.0M |
| EYPT | EyePoint Inc. | $0.3076 | +0.52% | $35.0M |
| PRPO | Precipio Inc. | $19.96 | -9.81% | $35.8M |
| RPID | Rapid Micro Biosystems Inc. | $0.7400 | +13.67% | $37.1M |
| HBIO | Harvard Bioscience Inc. | $8.91 | -5.96% | $40.7M |
| SEER | Seer Inc. | $1.48 | -5.73% | $82.6M |
| QTRX | Quanterix Corporation | $2.84 | -3.07% | $134.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier